GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Total Stockholders Equity: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
80 GF Score
Price ₹2,702.90
GF Value ₹2,722.69
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Total Stockholders Equity?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO +0.52% 80 Total Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 80/100 and a GF Value™ of ₹2,722.69 (Fairly Valued). The stock has 3 warning signs investors should review.

GlaxoSmithKline Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. GlaxoSmithKline Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 was ₹N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. GlaxoSmithKline Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 was .

GlaxoSmithKline Pharmaceuticals  (NSE:GLAXO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

GlaxoSmithKline Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0-0)/169.406
=N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

GlaxoSmithKline Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Total Stockholders Equity Related Terms

GlaxoSmithKline Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Total Stockholders Equity Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26,629.56 17,412.73 17,776.40 19,513.11 22,674.13

GlaxoSmithKline Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 17,077.00 0.00 22,674.13 0.00
NSE:GLAXO
80GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of ₹0 Mil mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Total Stockholders Equity of ₹0 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' Total Stockholders Equity too high?
GlaxoSmithKline Pharmaceuticals' current Total Stockholders Equity is ₹0 Mil. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Total Stockholders Equity compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' Total Stockholders Equity of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current Total Stockholders Equity is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,722.69, compared to a current price of ₹2,702.90 — trading 0.7% below its estimated fair value. The current Total Stockholders Equity is ₹0 Mil. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Total Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,702.90 is trading 0.7% below its estimated GF Value™ of ₹2,722.69. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Total Stockholders Equity: ₹0 Mil
  • GF Value™: ₹2,722.69 vs. price of ₹2,702.90 (0.7% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
80GF Score

Get the complete analysis for NSE:GLAXO

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,702.90
Price
₹2,722.69
GF Value